Day One Biopharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vestal Point Capital, LP and Ryan Wilder have filed an amendment reporting a 0% beneficial ownership stake in Day One Biopharmaceuticals, Inc.
NASDAQ
Atlas Venture Fund XI, L.P. and related entities have filed a Schedule 13G, reporting 0% beneficial ownership of Day One Biopharmaceuticals, Inc. common stock as of March 31, 2026.
NASDAQ
FMR LLC and Abigail P. Johnson have filed a Schedule 13G, reporting beneficial ownership of 23,639.69 shares of Day One Biopharmaceuticals common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Day One Biopharmaceuticals Inc. following an internal realignment.
NASDAQ
Glazer Capital, LLC and Paul J. Glazer have reported a 5.4% beneficial ownership stake in Day One Biopharmaceuticals, Inc.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Day One Biopharmaceuticals Inc. as of December 31, 2025.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 9.9% beneficial ownership stake in Day One Biopharmaceuticals Inc. as of September 30, 2025.
NASDAQ
SCHEDULE: RA Capital Exits Day One Biopharma Stake
RA Capital Management and its affiliates have reported zero beneficial ownership in Day One Biopharmaceuticals, Inc. as of June 30, 2025.
NASDAQ
FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 11.2% in Day One Biopharmaceuticals Inc., holding over 11.3 million shares.
NASDAQ
BlackRock, Inc. has reported a 5.8% beneficial ownership stake in Day One Biopharmaceuticals, Inc., holding 5,849,917 shares of common stock.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.7% passive beneficial ownership stake in Day One Biopharmaceuticals, Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: RA Capital Management and Affiliates Maintain Significant Passive Stake in Day One Biopharmaceuticals
RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, disclosing a continued passive beneficial ownership of 5.7% in Day One Biopharmaceuticals, Inc. as of December 31, 2024.
NASDAQ
FMR LLC and its Chief Executive Officer, Abigail P. Johnson, have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 12.8% of Day One Biopharmaceuticals Inc.'s common stock as of December 31, 2024.